The findings of previous studies as well our present results indicate that ESBL and AmpC-β-lactamase-producing isolates are usually resistant to others antibiotics such as trimethoprim/sulfamethoxazole and fluoroquinolones (
24,
25). The rate of resistance to imipenem was very low; this is similar to the results of others studies conducted in Iran and worldwide. Thus, imipenem is still the most active agent against ESBL and AmpC-β-lactamase-producing
E. coli isolates (
2,
26-
28). However, in the present study, two isolates were found to be resistant to imipenem; thus, resistance to this antibiotic may increase in the future (
2,
29). Interestingly, in this study, the diameter of the inhibition zone around the CO disk (colistin) was zero in 4 (7.8%) isolates from inpatients. Usually, colistin not used in the treatment of infections caused by
E. coli, therefore outbreaks of infections caused by gram-negative bacilli that are resistant to colistin pose a global threat (
30).
ESBL was detected in 23/54 (42.5%) of the isolates recovered from outpatients, and 17/23 (74%) of them harbored the
blaTEM and
blaSHV genes (
Table 3). The prevalence of resistance to five or more antibiotics was higher among the outpatient than the inpatient isolates: more than 70% of the outpatient isolates were MDR. Thus, MDR strains are common in outpatients in Kerman, Iran. Moreover, the prevalence of antibiotic resistance was somewhat higher in the outpatient isolates than in the inpatient isolates. This finding is similar to other studies conducted in Iran. All these studies indicate that in the near future, several antibiotics such as CIP and SXT will be useless in empirical therapy of uncomplicated UTIs in the community (
24,
25,
31). The spread of antibiotic resistance is related to healthcare-related behaviors and the environmental policies/laws in place. Inappropriate use of antibiotics, ineffective infection control and hygiene practices are behavioral factors, and the extensive use of antibiotics in agriculture is related to the environmental policies implemented (
32). In Iran, it is not clear whether ESBL and AmpC-producing isolates of
E. coli are present in the community, but high prevalence of community-acquired ESBL-producing isolates has been reported in other countries in Europe, Asia and USA (
24,
25). In our study, we found a high rate of resistance in community uropathogenic
E. coli against extended-spectrum cephalosporins (such as CAZ, CTX and CPM) and CIP. Moreover, the prevalence of ESBL-positive isolates in the inpatients was decreased from 63% to 37.25% compared to 2010, but the prevalence was increased in the outpatients (
33). Prevalence of ESBL-producing
E. coli in other regions of Iran, it is from 15.62% in Mashhad to 89.8% in Tehran (
26-
28). According to the results of our previous studies, the prevalence of ESBL and AmpC-producing
E. coli in hospitalized patients was higher: 63% in inpatients vs. 9.6% in outpatients (
26,
27,
29). In this studies, the prevalence of
blaTEM was 37.2% and
blaSHV was not detected in the inpatient isolates. However, these results are not in agreement with those of Abdi et al., who have reported the prevalence of
blaTEM and
blaSHV to be 82% and 65%, respectively (
34). Moreover, our results are not in agreement with those of Karimi et al., who have reported the prevalence of
blaSHV to be 15% in Tehran (
35). This difference between different regions of Iran could be related to behavioral factors or environmental policies. To date, AmpC-β-lactamase has been identified in clinical isolates recovered from hospitalized patients (
36). In our study, as only two isolates harbored AmpC-β-lactamase, it may imply that AmpC is not prevalent in this particular community in our region. These results indicate that AmpC-β-lactamase-producing community
E. coli isolates may not be important for public health, especially in UTI patients in Kerman, Iran. However, the prevalence of AmpC-β-lactamase-producing
E. coli
in the community in Kerman, Iran, is lower than in other countries such as the Netherlands (23%) (
36).